This article is more than 5 years old. Information may no longer be current.
Salix, Bausch Health Subsidiary Enter Deal to Develop Late-stage Therapy for IBD
Click Here to Manage Email Alerts
Salix Pharmaceuticals and Mitsubishi Tanabe Pharma Corporation, a subsidiary of Bausch Health, have entered an exclusive licensing agreement to develop and commercialize amiselimod, a late-stage oral compound that targets the sphingosine 1-phosphate (S1P) receptor, to treat inflammatory bowel disease, according to a company press release.
“For patients living with IBD, amiselimod represents an opportunity to develop an oral, non-immunogenic treatment as an alternative to biologics and other available therapies,” Mark McKenna, president of Salix Pharmaceuticals, said in the release. “[This] announcement reflects Salix’s commitment to serving the unmet needs of gastrointestinal patients and to offering health care providers with new treatment options to consider when they are managing patients who suffer from this chronic, life-long condition.”
Under the agreement, according to the release, Mitsubishi Tanabe grants Bausch Health exclusive rights to develop and commercialize MT-1303 (amiselimod) worldwide, except for Japan and other countries in Asia, in all fields, except neurology, rheumatology and certain rare dermatology diseases. Bausch Health, according to the release, plans to initiate development of the therapy in ulcerative colitis.